Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
TBC | garadacimab | Hereditary angioedema (HAE) | Pending | |||
TBC | exagamglogene autotemcel | Sickle cell disease (SCD) | Active | |||
TBC | exagamglogene autotemcel | Transfusion-dependent β-thalassemia | Active | |||
TBC | momelotinib | Myelofibrosis | Received | |||
TBC | clindamycin plus benzoyl peroxide and adapalene | acne vulgaris | Active | |||
TBC | ivosidenib | Acute myeloid leukemia (AML) | Active | |||
TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Pending | |||
TBC | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Active | |||
TBC | donanemab | Alzheimer disease | Pending | |||
TBC | talquetamab | Relapsed or refractory multiple myeloma | Active | |||
TBC | etonogestrel | Prevention of pregnancy | Withdrawn | |||
TBC | ravulizumab | Paroxysmal nocturnal hemoglobinuria. | Withdrawn | |||
TBC | abaloparatide | Osteoporosis, postmenopausal women | Withdrawn | |||
TBC | tirzepatide | Diabetes mellitus, type 2 | Cancelled | |||
TBC | halobetasol propionate and tazarotene | Psoriasis, moderate to severe plaque | Withdrawn | |||
TBC | daprodustat | Anemia due to chronic kidney disease | Withdrawn | |||
TBC | ferumoxytol | Iron deficiency anemia | Withdrawn | |||
TBC | Darunavir / cobicistat | HIV infection | Withdrawn | |||
TBC | zolbetuximab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Pending | |||
TBD | Entrectinib | Withdrawn | ||||
TBD | Cabozantinib | Withdrawn | ||||
TBD | Bevacizumab | Cancelled | ||||
TBD | Rituximab | Cancelled | ||||
TBD | Trastuzumab | Cancelled | ||||
Tecartus | brexucabtagene autoleucel | Mantle cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete |